Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
RFK Jr. says he's following 'gold standard' science. Here's what to know - 2The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- 3JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- 4Which Diet Prompts the Incomparable Wellbeing Results?
- 5French rapper Gims placed under investigation for 'aggravated money laundering'
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Vote in favor of the Top Vegetable for Senior
- Manual for 6 famous sorts of cheddar
- Hungary's 'water guardian' farmers fight back against desertification
- Remote Headphones: Improve Your Sound Insight
- At least 36 dead in major fire in Hong Kong residential blocks
- Must-See Public Parks from Around the Globe
- 10 Activities to Lift Your Consume and Bust Your Stomach
